Chemosensitivity testing

Cancer doctors principally rely on the statistical analysis of large treatment trials, to decide which drugs to use for specific cancers. There is a growing interest, however, in personalised cancer therapy, which involves identifying those treatments which may work best for an individual’s cancer. Chemosensitivity testing is one method of doing this.
Chemosensitivity testing involves testing an individual’s cancer cells in the laboratory to see which drugs demonstrate the best response. It therefore provides guidance about which treatments may be best for the individual in clinical practice.
The RGCC test is a blood test (or sometimes tissue). Tumour cells are identified and isolated from the sample for the following analysis:
• Viability testing of chemotherapy drugs
• Genetic profiling for guidance about targeted therapies eg;
monoclonal antibodies
• Viability testing (and identification of mechanisms of action) of natural substances which may be used as part of a complementary treatment strategy .
The results are presented in a written report which your doctor can use to help guide your treatment options and choices.
Information Downloads:
ISO 17025:2008
We are pleased to announce that the RGCC laboratory has received
accreditation ISO 17025:2008 with specific reference to CTC/CSC isolation and immunophenotyping; cancer cell culture viability/cytotoxicity assays and gene expression assays. Sensitivity and specificity data will be available
via this site shortly.
Monday, May 28th, 2012
RGCC-Europe N&W Ltd
Due to the increased interest in RGCC’s work in Europe, RGCC-UK has expanded to include the provision of tests in North West Europe. We are the branch office for RGCC in the UK, Ireland, Scandinavia (Norway, Finland, Sweden and Denmark), Spain, Portugal, Hungary and Romania.
Monday, November 21st, 2011










